Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Bioventix ( (GB:BVXP) ).
Bioventix plc, the AIM-listed UK antibody developer and supplier, focuses on high-affinity monoclonal antibodies for clinical diagnostics and provides a broad portfolio of sheep-derived reagents to major multinational diagnostics firms. Its products are used in automated immunoassays for blood testing across a range of diseases and conditions, underpinning the company’s niche but globally integrated market position.
The company has appointed Chris Yates as an independent non-executive director, effective 1 March 2026, bringing over two decades of board-level experience in listed life sciences and diagnostics businesses. His track record at Abingdon Health and other AIM-listed diagnostics firms is expected to bolster Bioventix’s governance, commercial insight and strategic oversight as it continues to serve leading clinical diagnostics customers worldwide.
The most recent analyst rating on (GB:BVXP) stock is a Buy with a £1856.00 price target. To see the full list of analyst forecasts on Bioventix stock, see the GB:BVXP Stock Forecast page.
Spark’s Take on GB:BVXP Stock
According to Spark, TipRanks’ AI Analyst, GB:BVXP is a Outperform.
The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).
To see Spark’s full report on GB:BVXP stock, click here.
More about Bioventix
Bioventix plc is a UK-based specialist in developing and commercially supplying high-affinity monoclonal antibodies for clinical diagnostics, particularly automated immunoassays used in blood testing. Its sheep-derived antibodies serve global multinational diagnostics companies and support tests for conditions including heart disease, cancer, fertility, thyroid disorders and drug abuse.
Average Trading Volume: 7,367
Technical Sentiment Signal: Sell
Current Market Cap: £84.9M
Find detailed analytics on BVXP stock on TipRanks’ Stock Analysis page.